content: <PAGE>
                    SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  
  
  Date  of  Report  (Date of earliest event reported)       JUNE 10, 1996 
  
                                          ENZON, INC.
  
                    (Exact  name  of  registrant  as  specified  in its charter)
  
  
  
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
  
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  
  
  Registrant's telephone number, including area code    (908) 980-4500
  
  
  
  
       (Former name or former address, if changed since last report)
  
  
  
  
  
  
  
  
  
  <PAGE>
  ITEM 5.  OTHER EVENTS
  
            Enzon,  Inc.  ("Enzon"  or the "Company") announced that  it  has
  exercised 150,000 warrants to purchase common stock of Neoprobe Corporation
  and sold the stock for a net profit  of  approximately  $1  million,  after
  payment  to  Neoprobe of the aggregate average exercise price of $10.50 per
  share.  The warrants  were  part  of  the  compensation  Enzon received for
  licensing its Single-Chain Antigen-Binding (SCA(R)) protein  technology  to
  Neoprobe  for  use  with  Neoprobe's  Radioimmunoguided  Surgery  (RIGS(R))
  product  under  the  license  agreement  originally  signed  in  1992.  The
  warrants  were  due  to  expire  in  1996.  Enzon will also be entitled  to
  receive additional payments per product  upon  the achievement of specified
  development  milestones  and  royalties  on sales of  any  future  products
  developed by Neoprobe that utilize Enzon's SCA technology.
  
  
  
  
  <PAGE>
  
  
  
                              SIGNATURES
  
  
       Pursuant to the requirements of the Securities  Exchange  Act of 1934,
  
  the  Registrant  has duly caused this report to be signed on its behalf  by
  
  the undersigned hereunto duly authorized.
  
  
  
  
  Dated:  June 24, 1996
  
  
  
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /s/KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial
                                           Officer
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 2592}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "96585025"}, "business-address": {"street1": "20 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  Date  of  Report  (Date of earliest event reported)       JUNE 10, 1996 
  
                                          ENZON, INC.
  
                    (Exact  name  of  registrant  as  specified  in its charter)
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  Registrant's telephone number, including area code    (908) 980-4500
  
       (Former name or former address, if changed since last report)
  ITEM 5.  OTHER EVENTS
  
            Enzon,  Inc.  ("Enzon"  or the "Company") announced that  it  has
  exercised 150,000 warrants to purchase common stock of Neoprobe Corporation
  and sold the stock for a net profit  of  approximately  $1  million,  after
  payment  to  Neoprobe of the aggregate average exercise price of $10.50 per
  share.  The warrants  were  part  of  the  compensation  Enzon received for
  licensing its Single-Chain Antigen-Binding (SCA(R)) protein  technology  to
  Neoprobe  for  use  with  Neoprobe's  Radioimmunoguided  Surgery  (RIGS(R))
  product  under  the  license  agreement  originally  signed  in  1992.  The
  warrants  were  due  to  expire  in  1996.  Enzon will also be entitled  to
  receive additional payments per product  upon  the achievement of specified
  development  milestones  and  royalties  on sales of  any  future  products
  developed by Neoprobe that utilize Enzon's SCA technology.
  SIGNATURES
  
       Pursuant to the requirements of the Securities  Exchange  Act of 1934,
  
  the  Registrant  has duly caused this report to be signed on its behalf  by
  
  the undersigned hereunto duly authorized.
  
  Dated:  June 24, 1996
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /s/KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial
                                           Officer